JLPC(SH:600513) Shang Hai Zheng Quan Bao·2025-09-12 20:04Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. plans to acquire certain real estate and land use rights from its controlling shareholder's subsidiary, with a transaction price of 74.5 million RMB (excluding tax) based on an asset appraisal report [2][4][14]. Summary by Sections 1. Overview of Related Transactions - The transaction involves the acquisition of part of the buildings and land use rights from Princes (Anqing) Pharmaceutical Technology Co., Ltd., a subsidiary of Jiangsu Lianhuan Pharmaceutical Group Co., Ltd. [2][4]. - The transaction is classified as a related party transaction and does not constitute a major asset restructuring as defined by regulations [3][4]. 2. Transaction Details - The transaction price is set at 74.5 million RMB (excluding tax), based on the appraisal results from Tianyuan Asset Appraisal Co., Ltd. [2][4][14]. - The transaction aims to enhance the stability and risk resistance of the company's assets through better resource allocation [5][18]. 3. Approval Process - The transaction has been approved by the company's independent directors, board of directors, and supervisory board, with related directors abstaining from voting [3][6][20]. - The transaction requires further approval from the shareholders' meeting and must comply with state-owned asset approval and transfer registration procedures, indicating potential uncertainties in completion [3][8]. 4. Financial and Asset Information - The transaction involves the purchase of 11 buildings and 7 structures, totaling an area of 20,912.10 square meters, and a land use right of 26,925.78 square meters located in Anqing [10][11]. - The assets are reported to be in normal use and meet operational needs, with clear ownership and no encumbrances [11][14]. 5. Impact on the Company - The transaction is expected to optimize resource allocation and expand asset scale, thereby enhancing the overall strength of the company [5][18]. - The management believes that the transaction will not adversely affect the company's financial status or operational results, nor will it harm the interests of shareholders, especially minority shareholders [18][20].